Introduction
Immune thrombocytopenia (ITP) remains one of the best characterized human autoimmune diseases. Although some other mechanisms might be involved, it mainly results from the production of autoantibodies against platelet antigens and thereby from the premature destruction of platelets [1] . Treatment is required at least in cases where the affected patients develop bleeding or a bleeding risk. However, none of the currently available therapies, including corticosteroids, intravenous high-dose immunoglobulin G (IVIG), anti-D, rituximab, splenectomy or immunosuppressive drugs, are invariably effective, and a good response (platelet counts > 50,000/μl) cannot be predicted in a single native, untreated patient. Furthermore, current standard therapies are unspecific and are largely based on selective or unselective immunosuppression [2] [3] [4] [5] .
During the last decade, the thrombopoietin receptor agonists (TPOs) romiplostim and eltrombopag have been increasingly used in the treatment of patients with ITP. Several well designed multicenter studies [6] [7] [8] [9] [10] [11] [12] [13] have demonstrated an increase in platelet counts in the majority of enrolled patients. Treatment with both drugs is generally effective, safe, and the majority of side effects observed are mild. However, the aforementioned studies involved a somewhat selective study population and a relatively small number of patients. Meanwhile, it became obvious that both drugs may indeed cause, at least in isolated cases, severe or even dangerous adverse reactions, including thromboembolic events, arthralgias, increase of bone marrow fibrosis, and myeloproliferative neoplasias [6] [7] [8] [9] [10] [11] [12] [13] .
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Patients and Methods
All patients (n = 65) (table 1) included in this observational study suffered from chronic ITP (61 primary ITP; 4 secondary ITP) and were treated from one clinician between July 2007 and May 2015. Treatment with TPOs was initiated only in patients with refractory ITP or in patients who did not adequately respond to previous therapies, including corticosteroids, IVIG, rituximab, immunosuppressors, anti-D, and/or splenectomy (table 2). Response was defined as compensated primary hemostasis and an increase in platelet counts to >50,000/μl during the treatment with TPOs.
The study was approved by the local review board (EA2/058112), and informed consent was obtained from all patients.
Results
Until May 2015, we gave attention to 58 patients treated with eltrombopag and 32 patients treated with romiplostim. Treatment was initially commenced with eltrombopag in 55 and with romiplostim in 10 cases (table 1). During observation, several patients developed adverse reactions, or the medication remained ineffective despite dose escalation to 75 or even 100 mg/day eltrombopag or to 10 μg/kg romiplostim. All patients that did not show response to TPOs were further treated with immunosuppressive drugs or received splenectomy ( fig. 1, 2) .
Treatment with TPOs resulted in compensated primary hemostasis and an increase in platelet counts to >50,000/μl during observation in 36 of 58 patients (62%) receiving eltrombopag and in 24 of 32 patients (75%) treated with romiplostim.
Twelve responding patients treated with eltrombopag discontinued the treatment due to adverse reactions ( fig. 1, table 3 ) that occurred between 1 and 20 months after treatment initiation. The adverse reaction became tolerable in 1 patient after dose reduction of eltrombopag. In comparison, treatment with romiplostim was discontinued in 8 patients due to adverse reactions that occurred between 1 and 66 months after treatment initiation with romiplostim ( fig. 2, table 3 ). In addition, 11 patients discontinued the treatment with eltrombopag due to remission (normalization of platelet counts without any therapy; n = 4), lack of drug (n = 3), refusal by patient (n = 3), and pregnancy (n = 1). Similary, 3 other patients discontinued treatment with romiplostim due to lack of drug (n = 1), refusal by patient (n = 1), and splenomegaly (n = 1). So far, 14 of 58 patients (24%) treated with eltrombopag continued treatment ( fig. 1 ), whereas 15 of 32 patients (47%) treated with romiplostim continued treatment ( fig. 2) .
Eltrombopag was directly (with no wash-out phase) replaced by romiplostim in 9 of the 12 patients with adverse reactions and in 11 of the 22 non-responsive patients. Three unresponsive patients received romiplostim following splenectomy. In total, 23 patients replaced eltrombopag by romiplostim. All of the eltrombopag-responsive patients that changed therapy due to adverse reactions were observed to respond well to romiplostim too, whereas only 6 of the 11 eltrombopag non-responders were observed to directly respond to romiplostim ( fig. 1, table 4 ). All 3 patients that underwent splenectomy responded to romiplostim. One patient did not respond to romiplostim prior to splenectomy, but thereafter. In total, 19 of the 23 switched patients responded to romiplostim (table 4) . During observation, 5 of the 19 responding patients developed adverse reactions to romiplostim (table 4) . Seven of the eltrombopag responders with adverse reactions could be safely treated with romiplostim, and the remaining 2 patients also showed adverse reactions to romiplostim. In comparison, romiplostim was replaced by eltrombopag in 4 cases due to adverse reactions and in one case due to non-effectivity (table 4). Three of the former patients responded well to eltrombopag, whereas the latter patient did not respond to eltrombopag (table 4) . Three of the 5 switched patients developed adverse reactions to eltrombopag, and 2 of the responding patients with adverse reactions could be safely treated with eltrombopag. Seven patients were splenectomized prior to treatment with eltrombopag. Four of these patients responded to the drug, and 3 did not respond. Ten patients had a history of splenectomy prior to treatment with romiplostim. Six of these patients responded to the drug, and 4 did not respond. Three of the splenectomized romiplostim patients had been refractory to eltrombopag before splenectomy and responded to romiplostim post splenectomy.
In conclusion, treatment with eltrombopag and/or romiplostim was effective and continued under observation in 29 of 65 (45%) cases.
Discussion
Previous well designed, randomized and controlled studies have demonstrated, that TPOs are not only highly effective but also largely safe in the treatment of ITP [6 -13] . They showed response rates of 65-92% for romiplostim and of 57-88% for eltrombopag. The most frequent adverse reactions reported in those studies were considered to be mild to moderate reactions including headache, fatigue, arthralgia, myalgia, and gastrointestinal disorders. The frequencies of severe adverse reactions, e.g. thromboembolic events, bone marrow reticulin transformation or development of myeloproliferative diseases, were reported to be between 0 and 15%. However, 3 long-term (2-5 years) studies dealing also with the discontinuation rate caused by adverse reactions showed a drop-out rate of 3-4% for romiplostim, and of 13% for eltrombopag [10, 12, 13] . Moreover, an indirect comparison between patients who received TPOs for 24-26 weeks has demonstrated an overall durable response rate of 42% for eltrombopag and 49% for romiplostim [25] . More importantly, the increase of bone marrow fibrosis appears to be higher (20-31%) than has been suggested [26, 27] . Nevertheless, utilization of both drugs is increasing on a global scale. Our observational study presents data of patients treated from one hand. Compared with pivotal studies, our results show slight differences regarding the efficacy and adverse reactions of TPOs. The efficacy does not appear to be as high as previously suggested, and adverse reactions were found to occur more frequently than previously reported. One possible explanation for this discrepancy may be related to errors in statistical analyses which may occur in any medical research [14] [15] [16] . Previous studies dealing with patients treated with TPOs and placebo were more focused on platelet counts rather than on the clinical picture of the affected patients. In contrast, our study focused on the clinical course of each patient prior, during and after the treatment with eltrombopag and romiplostim. Thus, the occurrence of any adverse reaction during observation could be exactly characterized. With the exception of 2 patients that developed myeloproliferative diseases, all other adverse reactions observed in the patients reported here, abolished within a few days or weeks after cessation or replacement of the causative drug. In contrast, previous reports of adverse reactions in ITP patients may be easily misinterpreted. For example, fatigue is now a well-characterized phenomenon in ITP. We and others [17] [18] [19] have observed that fatigue predominantly occurs when platelet counts decrease to < 50,000/μl in most affected patients. Comparison of adverse reactions in patients either receiving drugs or a placebo has demonstrated that the difference between both groups is insignificant. In those studies, the correlation between fatigue and platelet counts has not been assessed [6, 9] . In our experience, arthralgia is a typical symptom observed in isolated cases of ITP. Fatigue and/or arthralgia often occur only when the platelet count is <50,000/μl. An immediate improvement of both symptoms is observed when platelet counts increase, spontaneously or by any therapy. Therefore, the data reported in pivotal studies regarding fatigue and arthralgia are, as we believe, not valid as platelet counts were not considered in affected cases. If we assume that the adverse reactions observed in our patients are indicative of true adverse reactions, treatment with TPOs resulted in adverse reactions in at least 33% of patients receiving eltrombopag (19 [7, 13, 20] were not performed. Therefore, the true incidence of adverse reactions may be higher than has been observed so far.
As observed in our and in other studies [21] [22] [23] [24] , switching between TPOs appears to be beneficial in regard to efficacy and adverse reactions; nevertheless, some patients remained refractory to both drugs (5 of 25 patients). Furthermore, adverse reactions cannot invariably be overcome by switching. This was observed in 2 patients in this study. One of these patients developed a severe skin rash that diminished by discontinuation of romiplostim and was re-stimulated by eltrombopag. In another patient treatment with both drugs resulted in significant arthralgia.
Based on our results with TPOs, we highly recommend a strict and continuous surveillance throughout the course of treatment as necessary. Treatment with TPOs has been demonstrated to result in an increased risk of severe or life-threatening adverse drug reactions. Furthermore, long-term data are still lacking.
As the available TPOs do not cure patients with ITP, a reconsideration of current therapies should be made, and focus should be turned to the development of more specific therapies, not only for ITP but also for other autoimmune diseases.
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